HIF1A and cancer: Moreover, the increased glycolytic activity under hypoxia promotes survival pathways, such as HIF-1α and AMPK, enhancing resistance to therapies [44]; consequently, cancer cells can survive and resist the apoptotic signals that typically arise from ROS accumulation during treatment.